ClinicalTrials.Veeva

Menu
T

Texas Retina Associates | Arlington, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
RO7200220
LX211
Lampalizumab
Aflibercept
Vamikibart
Abicipar Pegol
Triamcinolone Acetonide
bevacizumab
rapamycin

Parent organization

This site is a part of Texas Retina Associates

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 43 total trials

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (SIGLEC)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks...

Active, not recruiting
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Ranibizumab refill exchange

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (...

Enrolling
Wet Age-related Macular Degeneration
Drug: Tarcocimab tedromer
Drug: Aflibercept

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerabi...

Active, not recruiting
Diabetic Macular Edema
Drug: Ranibizumab
Other: Sham Procedure

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting
Ulcerative Colitis
Drug: Etrasimod

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2

Trial sponsors

Roche logo
Allergan logo
E
AbbVie logo
Jaeb Center for Health Research logo
Johns Hopkins University logo
Kodiak Sciences logo
L
National Institutes of Health (NIH) logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems